nei THIS MONTH IN
PSYCHOPHARMACOLOGY
Risk of Congenital Malformations With Stimulant Use During Pregnancy
February 16, 2018   

In a recent cohort study from the International Pregnancy Safety Consortium the relationship between intrauterine exposure to stimulants, such as methylphenidate and amphetamine and risk of...
 Continue reading (Members only)
NEW Steps from FDA To Mitigate Opioid Overprescribing
February 13, 2018   

Given the widespread epidemic of prescribed opioid use disorder, including an alarming 40 opioid-related overdose deaths per day, the US Food and Drug Administration (FDA) released on January 30, 2018 a revised "blueprint" regarding the prescription of opioids...
 Continue reading (Members only)
Can Cannabis Use Reduce Opioid Use?
February 9, 2018   

Given the ongoing prescription opioid use disorder epidemic as well as the increasing legalization and availability of marijuana, the authors sought to determine whether marijuana use reduced the non-medical use of prescribed opioids...
 Continue reading
Review: Benefits vs. Risks of Aripiprazole During Pregnancy
February 7, 2018   

A systematic literature search and review evaluated the available data on the use of aripiprazole during pregnancy, peripartum and lactation...
 Continue reading (Members only)
Treatment With Propranolol Before Trauma Memory Reactivation May Reduce PTSD Symptoms
February 4, 2018   

Researcher found that trauma memory reactivation under the influence of propranolol showed a substantial reduction in posttraumatic stress disorder (PTSD) symptoms...
 Continue reading (Members only)
CYP2C19 Genotype Affects Escitalopram Exposure and Therapeutic Failure
February 2, 2018   

A new study shows that genotyping of CYP2C19 can help predict the therapeutic responsiveness to escitalopram and contribute to personalizing antidepressant therapy for the individual patient...
 Continue reading (Members only)
First Clinical Trial of Intranasal Esketamine Shows Positive Results for Treatment-Resistant Depression
January 20, 2018   

A recent phase 2 clinical trial was conducted to assess the efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression (TRD)...
 Continue reading (Members only)
New APA Alcohol Guidelines
January 17, 2018   

At a recent meeting, the American Psychiatric Association (APA) Board of Trustees approved the APA Practice Guideline for the Pharmacological Treatment of Patients with Alcohol Use Disorder (AUD)...
 Continue reading
New Recommendations For Using Urine Testing Procedures To Monitor Antipsychotic Adherence
January 14, 2018   

Medication nonadherence is a tremendous issue in the care of serious mental illnesses such as schizophrenia, major depressive disorder, and bipolar spectrum disorders. Unfortunately, as many as 50% of patients taking antipsychotic medications do not take their medications as prescribed...
 Continue reading (Members only)
Pointing a Finger at Parkinson's Disease Dementia
January 12, 2018   

As many as 80% of patients with Parkinson's disease develop dementia (PDD)—a dementia that can be somewhat difficult to distinguish from Alzheimer's disease (AD). Appropriate diagnosis is key to planning as well as future application of disease-modifying treatments...
 Continue reading (Members only)
12345678910...
Top of Page